

## **NOTICE OF 31<sup>ST</sup> ANNUAL GENERAL MEETING**

Notice is hereby given that the 31<sup>st</sup> Annual General Meeting of the members of Mankind Pharma Limited will be held at a shorter notice on Tuesday, 9<sup>th</sup> August, 2022 at 11:00 AM at the registered office of the Company at 208, Okhla Industrial Estate, Phase – III, New Delhi - 110020, to transact the following business: -

### **ORDINARY BUSINESS**

1. To receive, consider and adopt:-
  - a. The Standalone Audited Financial Statements for the financial year ended 31<sup>st</sup> March, 2022 and the Reports of the Board of Directors and Auditors thereon.
  - b. The Consolidated Audited Financial Statements for the financial year ended 31<sup>st</sup> March, 2022 and the Reports of the Auditors thereon.
2. To appoint a Director in place of Mr. Ramesh Juneja (DIN: 00283399), who retires by rotation and being eligible, offers himself for re-appointment.
3. To consider, and if thought fit, to pass, with or without modification, the following resolution as an Ordinary Resolution: -

### **APPOINTMENT OF M/S BHAGI BHARDWAJ GAUR & CO., CHARTERED ACCOUNTANTS, AS JOINT STATUTORY AUDITOR OF THE COMPANY**

“RESOLVED THAT pursuant to Sections 139, 142 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modifications or re-enactment thereof, for the time being in force), M/s Bhagi Bhardwaj Gaur & Co., Chartered Accountants (Firm Registration No. 007895N) be and is hereby appointed as Joint Statutory Auditor of the Company in place of M/s Goel Gaurav & Co., Chartered Accountants (Firm Registration No. 022467C), the retiring Joint Statutory Auditor, to hold office from the conclusion of this Annual General Meeting until the conclusion of the 36<sup>th</sup> Annual General Meeting of the Company at such remuneration plus taxes as applicable and reimbursement of out of pocket expenses in connection with the audit as the Board of Directors may decide in this behalf.”

### **SPECIAL BUSINESS**

4. To consider, and if thought fit, to pass, with or without modification, the following resolution as an Ordinary Resolution: -

### **APPOINTMENT OF MR. VIVEK KALRA (DIN: 00426240) AS AN INDEPENDENT DIRECTOR OF THE COMPANY**

“RESOLVED THAT, pursuant to approval of the board of directors of the Company (the “Board” or “Board of Directors”) in its meeting held on 1<sup>st</sup> August, 2022 and the provisions of the Companies Act, 2013 along with the rules made thereunder, each as amended (“Companies Act”), Regulation 17 of the Securities and Exchange Board of

### **MANKIND PHARMA LIMITED**

India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”), and other applicable provisions thereof, if any, Mr. Vivek Kalra (DIN: 00426240) be and is hereby appointed as an Independent Director on the Board, who shall hold office for a term of five years commencing on 1<sup>st</sup> August, 2022, and not be liable to retire by rotation. Mr. Vivek Kalra who has submitted a declaration that he meets the criteria for appointment as an Independent Director under Section 149(6) of the Companies Act and who is eligible for appointment, shall be entitled to receive sitting fees for attending meetings of the Board or any committees thereof and commission on the profits as may be determined by the Board from time to time.

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and are hereby authorized to do all the acts, deeds and things which are necessary to the appointment of Mr. Vivek Kalra as an Independent Director of the Company.”

5. To consider, and if thought fit, to pass, with or without modification, the following resolution as an Ordinary Resolution: -

**APPOINTMENT OF MS. VIJAYA SAMPATH (DIN: 00641110) AS AN INDEPENDENT DIRECTOR OF THE COMPANY**

“**RESOLVED THAT**, pursuant to approval of the board of directors of the Company (the “Board” or “Board of Directors”) in its meeting held on 1<sup>st</sup> August, 2022 and the provisions of the Companies Act, 2013 along with the rules made thereunder, each as amended (“Companies Act”) Regulation 17 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”), and other applicable provisions thereof, if any, Ms. Vijaya Sampath (DIN: 00641110) be and is hereby appointed as an Independent Director on the Board, who shall hold office for a term of five years commencing on 1<sup>st</sup> August, 2022, and not be liable to retire by rotation. Ms. Vijaya Sampath who has submitted a declaration that she meets the criteria for appointment as an Independent Director under Section 149(6) of the Companies Act and who is eligible for appointment, shall be entitled to receive sitting fees for attending meetings of the Board or any committees thereof and commission on the profits as may be determined by the Board from time to time.

**RESOLVED FURTHER THAT** the Board of Directors of the Company be and are hereby authorized to do all the acts, deeds and things which are necessary to the appointment of Ms. Vijaya Sampath as an Independent Director of the Company.”

6. To consider and if thought fit, to pass, with or without modification, the following resolution as a Special Resolution: -

**APPROVAL FOR ADOPTION OF RESTATED ARTICLES OF ASSOCIATION OF THE COMPANY**

“**RESOLVED THAT**, pursuant to the provisions of Section 14 and other applicable provisions of the Companies Act, the applicable provisions of the Securities Contracts (Regulation) Act, 1956, as amended, the Securities Contracts (Regulation) Rules, 1957, as amended, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and the listing requirements

of the stock exchange(s) where the securities of the Company are proposed to be listed and in accordance with the enabling provisions of the memorandum and articles of association and subject to the applicable provisions of any other applicable law, the consent and approval of the shareholders of the Company be and is hereby accorded for substitution of the existing set of articles of association of the Company with the new set of articles of association of the Company, and the same be approved and adopted as the new articles of association of the Company in total exclusion and substitution of the existing articles of association of the Company. The new set of articles of association of the Company comprise two parts, Part A and Part B, of which Part B shall automatically terminate and cease to have any force and effect from the date of listing of Equity Shares pursuant to the Offer and the provisions of Part A shall come to be in effect and be in force, without any further corporate or other action.

**RESOLVED FURTHER THAT**, Board of Directors of the Company, be and are hereby authorized to do all such acts, deeds, matters and things as may be required to be done to give effect to the above resolution.

**RESOLVED FURTHER THAT**, a copy of the above resolution, certified to be true by any Director or the Company Secretary, be forwarded to concerned authorities for necessary actions.”

7. To consider and if thought fit, to pass, with or without modification, the following resolution as a Special Resolution: -

**APPROVAL OF THE ‘MANKIND EMPLOYEE STOCK OPTION PLAN 2022’ (“ESOP 2022”/ “PLAN”)**

**“RESOLVED THAT** pursuant to the provisions of Section 62(1)(b) and other applicable provisions, if any, of the Companies Act, 2013 and the provisions of Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014, provisions of the Securities and Exchange Board of India (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 (“SEBI SBEB & SE Regulations”) read with circulars, if any, issued thereunder to the extent applicable and any other applicable laws, the relevant provisions of the Memorandum and Articles of Association of the Company, and subject to such other approvals, permissions and sanctions as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions and sanctions, the approval of the members be and is hereby accorded to the ‘Mankind Employee Stock Option Plan 2022’ (“ESOP 2022” or “Plan”), authorising the Board of Directors of the Company (*hereinafter referred to as "Board" which term shall be deemed to include any committee including Nomination and Remuneration Committee, which the Board has constituted to exercise its powers, including the powers, conferred by this resolution*) to create, offer, and grant up to, not exceeding 81,75,274 (Eighty One Lacs Seventy Five Thousand Two Hundred Seventy Four) employee stock options (“Options”), in one or more tranches, from time to time, to or for the benefit of such eligible person(s) as designated within the meaning of the Plan (*other than promoters and persons belonging to the promoter group, independent directors and directors holding directly or indirectly more than 10% (ten percent) of the outstanding equity shares of the Company*), subject to their eligibility as may be determined under the Plan, exercisable into not more 81,75,274 (Eighty One Lacs

Seventy Five Thousand Two Hundred Seventy Four) equity shares of face value of Re.1/- (Rupee One) each fully paid-up, to be allotted to the option grantees by the Company, where one Option upon exercise shall convert in to one equity share of the Company subject to payment/ recovery of requisite exercise price and applicable taxes, on such further terms, conditions and in such manner as the Board may decide in accordance with the provisions of the applicable laws and the provisions of the Plan”.

**RESOLVED FURTHER THAT** the equity shares of the Company as specified hereinabove shall rank *pari passu* in all respects with the then existing equity shares of the Company.

**RESOLVED FURTHER THAT** in case of any corporate action(s) such as rights issues, bonus issues, merger and sale of division and others, if any additional equity shares are required to be issued by the Company to the option grantees for the purpose of making a fair and reasonable adjustment to the Options granted earlier, the ceiling in terms of number of equity shares specified above shall be deemed to be increased to the extent of such additional equity shares are required to be issued.

**RESOLVED FURTHER THAT** in case the equity shares of the Company are either sub-divided or consolidated, then the ceiling in terms of number of equity shares specified above shall automatically stand augmented or reduced, as the case may be, in the same proportion as the face value per equity share shall bear to the revised face value of the equity share of the Company after such sub-division or consolidation.

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to make modifications, changes, variations, alterations or revisions in the Plan or any Options granted thereunder, as it may deem fit, from time to time, in its sole and absolute discretion in conformity with the provisions of the Section 62(1)(b) of the Companies Act, 2013 read with Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014, relevant provisions of the SEBI SBEB & SE Regulations to the extent applicable, the Memorandum and Articles of Association of the Company and any other applicable laws.

**RESOLVED FURTHER THAT** the Company shall conform to the accounting policies prescribed from time to time under the applicable laws and after initial public offer its equity shares the relevant provisions of the SEBI SBEB & SE Regulations.

**RESOLVED FURTHER THAT** for the purpose of giving effect to this resolution, the Board be and is hereby authorised on behalf of the company to do all such acts, deeds, matters and things as it may, in its absolute discretion, deem necessary, expedient, proper or desirable and to settle all questions, difficulties or doubts that may arise in this regard at any stage including at the time of listing of the equity shares.

**RESOLVED FURTHER THAT** the Board be and is hereby authorised to delegate all or any powers conferred herein, to any committee of directors with a power to further delegate to any executives / officers of the company to do all such acts, deeds, matters and things as also to execute such documents, writings etc. as may be necessary in this regard.”

8. To consider and if thought fit, to pass, with or without modification, the following resolution as a Special Resolution: -

**APPROVAL OF GRANT OF EMPLOYEE STOCK OPTIONS TO THE EMPLOYEES OF SUBSIDIARY COMPANY(IES) OF THE COMPANY UNDER ‘MANKIND EMPLOYEE STOCK OPTION PLAN 2022’**

“**RESOLVED THAT THAT** pursuant to the provisions of Section 62(1)(b) and other applicable provisions, if any, of the Companies Act, 2013 and the Rules made there under, the provisions of Regulation 6 of the of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations 2021, as amended and enacted from time to time read with all circulars and notifications issued thereunder (“SEBI SBEB & SE Regulations”) to the extent applicable and any other applicable laws, the relevant provisions of the Memorandum and Articles of Association of the Company and subject further to such other approvals, permissions and sanctions as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions and sanctions, the consent of the members’ of the Company be and is hereby accorded authorizing the Board of Directors of the Company (*hereinafter referred to as the “Board” which term shall be deemed to include any Committee, including the Nomination and Remuneration Committee which the Board has constituted to exercise its powers, including the powers, conferred by this resolution and under Regulation 5 of the SEBI SBEB & SE Regulations to the extent applicable*) to offer, create, and grant from time to time, in one or more tranches, such number of employee stock options under the ‘Mankind Employee Stock Option Plan 2022’ (“ESOP 2022”/ “Plan”)’ within the limit prescribed therein to or for the benefit of such eligible person(s) as designated within the meaning of the Plan (*other than promoter or person belonging to the promoter group of the Company, independent director(s) and director(s) holding directly or indirectly more than 10% of the outstanding equity shares of the Company*), of any subsidiary company(ies) of the Company, whether in or outside India, as may be decided under the Plan exercisable into corresponding number of equity shares of face value of Re.1/- (Rupee One) each fully paid-up, where one employee stock option would convert in to one equity share upon exercise, on such terms and in such manner as the Board/ Committee may decide in accordance with the provisions of the applicable laws and the provisions of the Plan.

**RESOLVED FURTHER THAT**, Board of Directors of the Company, be and are hereby authorized to do all such acts, deeds, matters and things as may be required to be done to give effect to the above resolution.”

9. To consider and if thought fit, to pass, with or without modification, the following resolution as a Special Resolution: -

**TO APPROVE GRANT OF EMPLOYEE STOCK OPTIONS TO THE EMPLOYEES OF GROUP COMPANY(IES)/ASSOCIATE OF THE COMPANY UNDER ‘MANKIND EMPLOYEE STOCK OPTION PLAN 2022’**

“**RESOLVED THAT THAT** pursuant to the provisions of Section 62(1)(b) and other applicable provisions, if any, of the Companies Act, 2013 and the Rules made there under, the provisions of Regulation 6 of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations 2021, as amended and

enacted from time to time read with all circulars and notifications issued thereunder (“SEBI SBEB & SE Regulations”) to the extent applicable and any other applicable laws, the relevant provisions of the Memorandum and Articles of Association of the Company and subject further to such other approvals, permissions and sanctions as may be necessary and subject to such conditions and modifications as may be prescribed or imposed while granting such approvals, permissions and sanctions, the consent of the members’ of the Company be and is hereby accorded authorizing the Board of Directors of the Company (*hereinafter referred to as the “Board” which term shall be deemed to include any Committee, including the Nomination and Remuneration Committee which the Board has constituted to exercise its powers, including the powers, conferred by this resolution and under Regulation 5 of the SEBI SBEB & SE Regulations to the extent applicable*) to offer, create, and grant from time to time, in one or more tranches, such number of employee stock options under the ‘Mankind Employee Stock Option Plan 2022’ (“ESOP 2022”/ “Plan”)’ within the limit prescribed therein to or for the benefit of such eligible person(s) as designated within the meaning of the Plan (*other than promoter or person belonging to the promoter group of the Company, independent director(s) and director(s) holding directly or indirectly more than 10% of the outstanding equity shares of the Company*), of any group company(ies)/associate of the Company, whether in or outside India, as may be decided under the Plan exercisable into corresponding number of equity shares of face value of Re.1/- (Rupee One) each fully paid-up, where one employee stock option would convert in to one equity share upon exercise, on such terms and in such manner as the Board/ Committee may decide in accordance with the provisions of the applicable laws and the provisions of the Plan.”

**RESOLVED FURTHER THAT**, Board of Directors of the Company, be and are hereby authorized to do all such acts, deeds, matters and things as may be required to be done to give effect to the above resolution.”

10. To consider, and if thought fit, to pass, with or without modification, the following resolution as an Ordinary Resolution: -

**INCREASE IN INVESTMENT LIMITS FOR NON-RESIDENT INDIANS AND OVERSEAS CITIZENS OF INDIA**

**“RESOLVED THAT**, pursuant to approval of the Board in its meeting held on 19<sup>th</sup> July, 2022 and the applicable provisions of Foreign Exchange Management Act, 1999, as amended (“FEMA”), Foreign Exchange Management (Non-debt Instruments) Rules, 2019, as amended, Master Direction No. 11/2017-18 issued by the RBI, as amended up to date, the Consolidated Foreign Direct Investment Policy Circular of 2020, as amended and the Companies Act, 2013, as amended, and the rules and regulations notified thereunder (collectively referred to as the “Companies Act”) and subject to all applicable approvals, permissions and sanctions of the Reserve Bank of India (“RBI”), the Ministry of Finance, the Ministry of Corporate Affairs, Government of India and other concerned authorities and subject to such conditions as may be prescribed by any of the said concerned authorities while granting such approvals, permissions or sanctions which may be agreed to by the board of directors of the Company (“Board”), the limit of investment by NRIs and OCIs in the equity shares bearing face value of ₹ 1 each of the Company, including, without limitation, by subscription in the initial public offering in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure

Requirements) Regulations, 2018, as amended be fixed at 24% of the paid-up equity share capital of the Company.

**RESOLVED FURTHER THAT** Board of Directors of the Company are authorised to do all such acts, deeds, matters and things, including to settle any question, difficulty or doubt that may arise and to finalise and execute all documents and writings as may be necessary.

**RESOLVED FURTHER THAT**, a copy of the above resolution, certified to be true by any Director and/or the Company Secretary, be forwarded to concerned authorities for necessary actions.”

11. To consider, and if thought fit, to pass, with or without modification, the following resolution as an Ordinary Resolution: -

**RATIFICATION OF THE REMUNERATION OF COST AUDITOR FOR THE FINANCIAL YEAR 2022-23**

**"RESOLVED THAT** pursuant to Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory amendment(s), modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of ₹960,000/- (Rupees Nine Lakh Sixty Thousand Only) plus taxes as applicable and reimbursement of travel and out of pocket expenses, as approved by the Board on the recommendation of the Audit Committee, to be paid to M/s M. K. Kulshrestha & Associates, Cost Accountants, for conducting the cost audit for the financial year 2022-23, be and is hereby ratified and confirmed.”

**By order of the Board of Directors  
For Mankind Pharma Limited**

Sd/-

**Pradeep Chugh  
Company Secretary  
M. No. A18711**

Date: 5<sup>th</sup> August, 2022

Place: New Delhi

Regd. Office: 208, Okhla Industrial Estate

Phase – III, New Delhi 110 020

**NOTES: -**

1. The explanatory statement pursuant to Section 102 of the Companies Act, 2013 (“the Act”), relating to special business to be transacted at the Annual General Meeting (“AGM” or “Meeting”) is annexed. The explanatory statement relating to item no. 3 being ordinary business is also provided though not required as per Section 102 of the Act.
2. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON POLL ON HIS / HER BEHALF, AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY.** The instrument of Proxy, in order to be effective, should be duly completed,

stamped (if applicable), signed and must be deposited, either in person or through registered post, at the Registered Office of the Company at least 48 hours before the commencement of the Meeting. Pursuant to Section 105 of the Companies Act, 2013, a person can act as a proxy on behalf of not more than 50 Members and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A Member holding more than ten percent of total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder. A proxy form for the AGM is enclosed.

3. A Corporate Member intending to send its authorised representatives to attend the Meeting in terms of Section 113 of the Companies Act, 2013 is requested to send to the Company a certified true copy of the relevant Board Resolution authorizing such a representative to attend and vote on its behalf at the Meeting, together with the specimen signature(s) of the authorised representative(s).
4. Members/proxies are requested to bring the attendance slips duly filled in for attending the Meeting. Members holding shares in dematerialised form are requested to write their client ID and DP ID numbers. Only bonafide Members of the Company whose names appear on the Register of Members / Proxy holders in possession of valid attendance slips duly filled in and signed will be permitted to attend the meeting. The Company reserves the right to take all steps as may be deemed necessary to restrict non-members from attending the Meeting.
5. Members holding shares in dematerialized form are requested to submit the PAN and bank account details to their Depository Participants with whom they are maintaining their demat accounts, in case they have not submitted.
6. Members holding shares in dematerialized form are requested to notify any change in their e-mail address to the Depository Participants and always quote their DP ID and Client ID Numbers in all correspondence with the Company. Members are also requested to notify any change of address to their Depository Participants.
7. Register of Directors and Key Managerial Personnel and their shareholding and Register of Contracts or Arrangements in which Directors are interested, maintained under Sections 170 and 189 respectively of the Act and all documents referred to in the accompanying Notice and the Explanatory Statement, will be available for inspection by the Members at the AGM and at the Registered Office of the Company from Monday to Friday between 11:00 AM to 01:00 PM except on holidays, up to and including the date of AGM of the Company.
8. Information regarding particulars of Directors, as are required to be provided pursuant to Section 102 of the Companies Act, 2013 and Secretarial Standard - 2 on General Meetings issued by the Institute of Company Secretaries of India is enclosed to this Notice.
9. The Company's Registrar and Share Transfer Agents for correspondence is KFIN Technologies Private Limited, Selenium Building, Tower B, Plot No. 31-32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana 500032; Tel No. 040 – 6716 2222, Fax No. 040 – 2300 1153; Email: [venu.sp@kfintech.com](mailto:venu.sp@kfintech.com)
10. Since the meeting is being called at shorter notice, the format of shorter notice consent is enclosed herewith.
11. Route-map to the venue of the Meeting is provided at the end of the Notice.



**EXPLANATORY STATEMENT**  
**(Pursuant to Section 102 of the Companies Act, 2013)**

**ITEM NO. 3**

The members are informed that M/s Goel Gaurav & Co., Chartered Accountant, Joint Statutory Auditors shall retire at the conclusion of the forthcoming Annual General Meeting. The Board of Directors in their meeting held on 1<sup>st</sup> August, 2022 recommended the appointment of M/s Bhagi Bhardwaj Gaur & Co., Chartered Accountant as Joint Statutory Auditors of the Company in place of M/s Goel Gaurav & Co., Chartered Accountant for a term of 5 years from the conclusion of 31<sup>st</sup> Annual General Meeting till the conclusion of the 36<sup>th</sup> Annual General Meeting of the Company.

The Board recommends the resolution for approval of the members of the Company.

None of the directors, key managerial personnel and relatives of directors and/or key managerial personnel (as defined in the Companies Act, 2013) are concerned or interested in the proposed resolution, except in the ordinary course of business.

**ITEM NO. 4**

Mr. Vivek Kalra is proposed to be appointed as an Independent Director of the Company, in accordance with applicable laws, including the Companies Act, 2013 and the provisions of Regulation 17 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), each as amended. In this connection, the Board is of the opinion that Mr. Vivek Kalra fulfils the criteria for independent directors, as set out in the Companies Act, 2013, related rules framed thereunder and the SEBI Listing Regulations and that Mr. Vivek Kalra is independent of the management of the Company.

The Company has also received other necessary disclosures from Mr. Vivek Kalra as required under the Act. Mr. Vivek Kalra does not hold any shares of Mankind.

As per the provisions of Section 149 of the Act, Mr. Vivek Kalra shall hold office for a term of five (5) consecutive years on the Board of the Company and is not liable to retire by rotation.

In the opinion of the Board, Mr. Vivek Kalra is a person of integrity, fulfils the conditions specified in the Act and the Rules made thereunder and is independent of the Management of the Company. Having regard to the qualifications, experience and knowledge, the Board considers that his association would be of immense benefit to the Company and it is desirable to avail the services of Mr. Vivek Kalra as an Independent Director.

A brief profile of Mr. Vivek Kalra is provided as annexure to this Notice.

The terms and conditions of appointment of Mr. Vivek Kalra shall be open for inspection by the Members at the Registered Office of the Company during official hours on all working days till the date of the 31<sup>st</sup> Annual General Meeting.

The Board of Directors has recommended the appointment of such Director as an Independent Director for a term of five years subject to such Directors continuing to satisfy the criteria of

independence in terms of the Companies Act, 2013, the rules made thereunder and the SEBI Listing Regulations, and shall not be liable to retire by rotation.

The Board recommends the resolution for approval of the members of the Company.

None of the directors, key managerial personnel and relatives of directors and/or key managerial personnel (as defined in the Companies Act, 2013) are concerned or interested in the proposed resolution, except in the ordinary course of business.

#### **ITEM NO. 5**

Ms. Vijaya Sampath is proposed to be appointed as an Independent Director of the Company, in accordance with applicable laws, including the Companies Act, 2013 and the provisions of Regulation 17 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), each as amended. In this connection, the Board is of the opinion that Ms. Vijaya Sampath fulfils the criteria for independent directors, as set out in the Companies Act, 2013, related rules framed thereunder and the SEBI Listing Regulations and that Ms. Vijaya Sampath is independent of the management of the Company.

The Company has also received other necessary disclosures from Ms. Vijaya Sampath as required under the Act. Ms. Vijaya Sampath does not hold any shares of Mankind.

As per the provisions of Section 149 of the Act, Ms. Vijaya Sampath shall hold office for a term of five (5) consecutive years on the Board of the Company and is not liable to retire by rotation.

In the opinion of the Board, Ms. Vijaya Sampath is a person of integrity, fulfils the conditions specified in the Act and the Rules made thereunder and is independent of the Management of the Company. Having regard to the qualifications, experience and knowledge, the Board considers that her association would be of immense benefit to the Company and it is desirable to avail the services of Ms. Vijaya Sampath as an Independent Director.

A brief profile of Ms. Vijaya Sampath is provided as annexure to this Notice.

The terms and conditions of appointment of Ms. Vijaya Sampath shall be open for inspection by the Members at the Registered Office of the Company during official hours on all working days till the date of the 31st Annual General Meeting.

The Board of Directors has recommended the appointment of such Director as an Independent Director for a term of five years subject to such Directors continuing to satisfy the criteria of independence in terms of the Companies Act, 2013, the rules made thereunder and the SEBI Listing Regulations, and shall not be liable to retire by rotation.

The Board recommends the resolution for approval of the members of the Company.

None of the directors, key managerial personnel and relatives of directors and/or key managerial personnel (as defined in the Companies Act, 2013) are concerned or interested in the proposed resolution, except in the ordinary course of business.

**ITEM NO. 6**

In order to undertake the proposed public offer of the equity shares of the Company and list them on one or more recognized stock exchanges in India (the “Stock Exchanges”), the Company will be required to ensure that the articles of association of the Company (the “Articles of Association”) conform to the requirements prescribed by the Stock Exchanges prior to filing of the draft red herring prospectus with the Securities and Exchange Board of India and the Stock Exchanges. The Company therefore proposes to adopt a new set of Articles of Association that shall conform to the requirements and directions provided by the Stock Exchanges and contain such other articles as required by a public limited company under applicable laws (including the Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, each as amended). The new set of Articles of Association of the Company shall comprise two parts, Part A and Part B, which parts shall, unless the context otherwise requires, co-exist with each other until the commencement of the listing of the Equity Shares on the Stock Exchanges pursuant to the Offer. From the date of listing of the Equity Shares on the Stock Exchanges pursuant to the Offer (“Listing Date”), Part B of the new Articles of Association shall automatically terminate and cease to have any force and effect, and the provisions of Part A, as on the Listing Date, shall continue to be in effect and be in force, without any further corporate or other action, by the Company or by its shareholders.

A draft copy of the Articles of Association is available for inspection at the Company’s Registered Office during official hours on all working days till the date of the 31<sup>st</sup> Annual General Meeting.

Pursuant to the provisions of Section 14 of the Companies Act, 2013, as applicable, any amendment in Article of Association requires approval of the members of the Company by way of a special resolution.

The Board recommends the resolution for approval of the members of the Company.

None of the directors, key managerial personnel and relatives of directors and/or key managerial personnel (as defined in the Companies Act, 2013) are concerned or interested in the proposed resolution, except in the ordinary course of business.

**ITEM NOS. 7 TO 9**

The Company appreciates the critical role its key employees play in the organizational growth. It strongly feels that the value created by its key employees should be shared with them. To promote the culture of employee ownership and as well as to attract, retain, motivate, and incentivize senior and critical talents in line with corporate growth and creation of shareholders’ value, the Company intends to implement an employee stock option plan namely ‘Mankind Employee Stock Option Plan 2022’ (“ESOP 2022”/ “Plan”) for key employees including directors of the Company its subsidiary company(ies) and its group companies/associates as eligible under Rule 12 of Companies (Share Capital and Debentures) Rules, 2014 and as determined from time to time. The proposed Plan is in compliance with Section 62(1)(b) and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014, and the Securities and Exchange Board of India (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 (“SEBI SBEB & SE Regulations”) read with circulars, if any, issued thereunder to the extent applicable.

Accordingly, the Nomination and Remuneration Committee (“Committee”) and the Board of Directors of the Company (“Board”) at their respective meetings both held on 19<sup>th</sup> July, 2022 had approved the introduction of the Plan, subject to your approval.

**Particulars as required under the applicable laws:**

**a) Brief description of the scheme:**

The Plan provides for grant of employee stock options (“Options”) to the eligible employees including directors (collectively referred to as “employees”) of the Company, its subsidiary company(ies) and its group companies/associates, as may be permissible under the Companies Act and the SEBI SBEB & SE Regulations.

Upon vesting of Options, the eligible employees earn a right (but not obligation) to exercise the vested Options within the exercise period and obtain equity shares of the Company which shall be allotted by the company subject to receipt of exercise price and satisfaction of any tax obligation arising thereon.

The Nomination and Remuneration Committee (“Committee”) of the Company shall superintend and administer the Plan with terms of reference of such powers as delegated by the Board or as are available under the applicable laws. All questions of interpretation of the Plan shall be determined by the Committee as per terms of the Plan and applicable laws.

**b) Total number of Options to be granted:**

A total of 81,75,274 (Eighty One Lacs Seventy Five Thousand Two Hundred Seventy Four) Options would be available for being granted to the eligible employees of the Companies under the Plan. Each Option when exercised would be converted into one equity share of face value of Re.1/- (Rupee One) each fully paid-up.

Options lapsed or cancelled due to any reason including the reason of lapse of exercise period or due to resignation of the employees or otherwise, would be available for being re-granted. The Committee is authorized to re-grant such lapsed / cancelled Options as per the Plan.

In case of any corporate action(s) such as rights issues, bonus issues, merger and sale of division and others, a fair and reasonable adjustment will be made to the Options granted. Accordingly, if any additional equity shares are required to be issued by the Company to the option grantees for making such fair and reasonable adjustment, the ceiling of Options/ equity shares as aforesaid shall be deemed to increase to the extent of such additional equity shares issued.

**c) Identification of classes of employees entitled to participate in the Plan:**

- (i) a permanent employee of the Company who has been working in India or out of India; or
- (ii) a director of the Company, whether a whole-time director or not but excluding an independent director; or
- (iii) an employee as defined in clauses (i) or (ii) of a Subsidiary, in India or outside India; but shall does not include
  - a) an employee who is a Promoter or belongs to the Promoter Group;

- b) a director who either by himself or through his relatives or through any body-corporate directly or indirectly, holds more than 10% of the issued and subscribed Shares of the Company; and

Provided further that post Listing, the term “Employee” shall be defined as below in compliance with the SEBI SBEB & SE Regulations.

“Employee” shall mean -

- (i) an employee as designated by the Company, who is exclusively working in India or outside India; or
- (ii) a Director of the Company, whether a whole-time Director or not, including a non-executive Director who is not a Promotor or member of the Promoter Group, but excluding an Independent Director; or
- (iii) An Employee as defined in sub-clauses (i) or (ii), of a group company including Subsidiary Company or its Associate Company, in India or outside India, of the Company; but does not include-
  - a. an employee who is a Promotor or a person belonging to the Promoter Group; or
  - b. a Director who, either himself or through his relative or through any body-corporate, directly or indirectly, holds more than 10% of the outstanding equity shares of the Company.

**d) Appraisal process for determining the eligibility of the employees to employee stock options:**

The Options shall be granted to the employees as per eligibility criteria determined by the Committee as it deems fit, from time to time, which may include attributes like past performance, achievement of key performance indicators, future potential, etc.

**e) Requirements of vesting and period of vesting:**

The Options granted shall vest so long as the employee continues to be in the employment or service on the date of vesting and must neither be serving his notice of resignation nor termination of employment/ service on such date of vesting. The Committee may, at its discretion, lay down certain performance metrics on the achievement of which the granted Options would vest, the detailed terms and conditions relating to such performance-based vesting, and the proportion in which Options granted would vest (subject to the minimum and maximum vesting period as specified below).

The vesting period of Options granted shall vest in not earlier than 1 (one) year and not more than 4 (four) years from the date of grant of such Options. The exact proportion in which and the exact period over which the Options would vest would be determined by the Committee at the time of grant, subject to the minimum vesting period of one year from the date of grant of Options.

**f) The maximum period within which the Options shall be vested:**

The Options granted shall vest in not more than 4 (four) years from the date of grant of such Options.

**g) The exercise price or pricing formula:**

The exercise price per Option shall be determined by the Committee which in any case shall not be less than the face value of the share of the Company as on date of grant.

**h) The exercise period and the process of exercise:**

The vested Options can be exercised by the employees within a maximum exercise period of 5 (five) years from the date of the vesting of such Options.

However, in case of death and permanent incapacity while in employment or service, the exercise period shall be up to a maximum of exercise period of 36 months commencing from the date of death or permanent incapacity, as the case may be.

The Options will be exercised by the employees by a written application to the designated officer of the Company in such manner, and on execution of such documents, as may be prescribed in this regard from time to time.

The Option will lapse if not exercised within the specified exercise period.

**i) Lock-in period:**

The shares arising out of exercise of vested Options would not be subject to any lock-in period after such exercise except such restrictions as prescribed under the applicable laws specifically in connection with or after listing of company's shares.

**j) Maximum number of Options to be issued per employee and in aggregate:**

Maximum number of Options that may be granted to any individual employee under the Plan shall not exceed 400,000 (four lacs) Options. For maximum number of Options to be granted in aggregate, see b) above.

**k) Maximum quantum of benefits to be provided per Employee:**

Apart from grant of Options as stated above, no monetary benefits are contemplated under the Plan.

**l) Whether the Plan is to be implemented and administered directly by the Company or through a trust:**

The Plan shall be implemented and administered directly by the Company, through the Nomination and Remuneration Committee (which shall be designated as the Compensation Committee for the purposes of the Plan) duly constituted by the Board from time to time. Provided further that if prevailing circumstances so warrant, the Company may change the mode of implementation of the Plan subject to the condition that a fresh approval of the shareholders by a special resolution is obtained prior to implementing such a change and that such a change is not prejudicial to the interests of the employees

**m) Whether the Plan involves new issue of shares by the company or secondary acquisition by the trust or both:**

The Plan contemplates new issue of shares by the Company.

**n) The amount of loan to be provided for implementation of the scheme(s) by the company to the trust, its tenure, utilization, repayment terms, etc.:**

This is currently not contemplated under the Plan

**o) Maximum percentage of secondary acquisition (subject to limits specified under the regulations) that can be made by the trust for the purposes of the scheme(s):**

This is not relevant under the Plan as the Plan contemplates to use fresh shares to be issued by the Company.

**p) Method of option valuation:**

To calculate the employee compensation cost, the Company shall use the fair value method for valuation of the Options granted as per prescribed under Ind-AS 102 or under any relevant accounting standard as notified by appropriate authorities from time to time.

**q) The conditions under which Options vested in employees may lapse:**

The vested Options shall lapse in case of termination of employment due to misconduct or due to breach of Company policies or the terms of employment. Further, irrespective of employment status, in case vested Options are not exercised within the prescribed exercise period, then such vested Options shall lapse.

**r) The specified time period within which the employee shall exercise the vested Options in the event of a proposed termination of employment or resignation or retirement of employee:**

In case of resignation / termination without misconduct, all vested Options can be exercised by the employee on the last working day, or by the date of expiry of exercise period as specified in the grant letter, whichever is earlier. In case of retirement of an employee, all vested Options as on the date of retirement can be exercised by the Option grantee within 12 (Twelve) months from the date of Retirement. which shall not exceed the maximum exercise period stated above.

**s) Terms & conditions for buyback, if any, of specified securities/ Options covered granted under the Plan:**

Subject to the provisions of the then prevailing applicable laws, the Committee shall determine the procedure for buy-back of specified securities issued pursuant to exercise of Options granted under the Plan if to be undertaken at any time by the Company, and the applicable terms and conditions thereof.

**t) Disclosure and Accounting Policies:**

The Company shall comply with the disclosure and the accounting policies prescribed as per prevailing accounting guidelines and upon listing of securities of the Company, the Company shall comply with the accounting policies and disclosure requirements as prescribed under Regulation 15 of the SEBI SBEB & SE Regulations.

**u) Declaration:**

In case, the Company opts for expensing of share-based employee benefits using the intrinsic value, the difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the Options and the impact of this difference on profits and on Earning Per Share (EPS) of the Company shall also be disclosed in the Directors' Report.

A draft copy of the Plan is available for inspection at the Company's Registered Office during official hours on all working days till the date of the 31<sup>st</sup> Annual General Meeting.

The Board recommends the resolution for approval of the members of the Company.

None of the Directors, or Key Managerial Personnel of the Company and their relatives are in any way, concerned or interested in these resolutions, except to the extent of the securities that may be offered to them under the Plan.

**ITEM NO. 10**

In terms of Foreign Exchange Management Act, 1999, as amended, the Foreign Exchange Management (Non-debt Instruments) Rules, 2019, as amended (the “FEMA Regulations”), and the Consolidated Foreign Direct Investment Policy Circular of 2020, as amended (together with the FEMA Regulations, the “FEMA Laws”), the Non-resident Indians (“NRI”) and Overseas Citizens of India (“OCI”), together, can acquire and hold on repatriation basis up to an aggregate limit of 10% of the paid up equity share capital of an Indian company. The FEMA Laws further provide that the limit of 10% can be further increased up to 24%, by passing a special resolution to that effect by the shareholders and followed by necessary filings with Reserve Bank of India. Considering the proposal of intending to get the equity shares of the Company listed on one or more recognized stock exchanges in India, the Board of Directors of the Company has, at its meeting held on 19<sup>th</sup> July, 2022, proposed, subject to the approval of the shareholders by way of a special resolution, to increase the foreign investment limit of NRIs and OCIs on repatriation basis to 24% of the paid up equity share capital of the Company.

The Board recommends the resolution for approval of the members of the Company.

None of the directors, key managerial personnel and relatives of directors and/or key managerial personnel (as defined in the Companies Act, 2013) are concerned or interested in the proposed resolution, except in the ordinary course of business.

### **ITEM NO. 11**

The members are informed that in accordance with Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the remuneration payable to the Cost Auditor as recommended by the Audit Committee and approved by the Board has to be ratified by the Members of the Company.

The Board of Directors at its meeting held on 1 August, 2022 , on the recommendation of the Audit Committee, has re-appointed M/s M.K. Kulshrestha & Associates, Cost Accountants as the Cost Auditor of the Company for the financial year 2022-23 at a remuneration of ₹960,000/- plus taxes as applicable and reimbursement of travel and out of pocket expenses.

The Board recommends the resolution for approval of the members of the Company.

None of the directors, key managerial personnel and relatives of directors and/or key managerial personnel (as defined in the Companies Act, 2013) are concerned or interested in the proposed resolution, except in the ordinary course of business.

**By order of the Board of Directors  
For Mankind Pharma Limited**

Date: 5<sup>th</sup> August, 2022  
Place: New Delhi  
Regd. Office: 208, Okhla Industrial Estate  
Phase – III, New Delhi 110 020

Sd/-  
**Pradeep Chugh**  
Company Secretary  
M. No. A18711



**Annexure to the Notice of AGM**

Details of Directors seeking appointment at the Meeting

**MR. VIVEK KALRA**

<b>S. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Age	58 years
2.	Qualifications	Mr. Vivek Kalra is B.Tech from IIT Madras and MBA from Stanford University.
3.	Experience	Mr. Vivek Kalra is the Founder and Managing Partner of Singular Capital – an investment manager focused on the mid-cap listed equity universe in India. Previously, he was a Partner at Capital Group Private Markets, based in Singapore, and led/co-led investments across various emerging markets and sectors, with a substantial focus on India. He has served on various investee company boards, including Mindtree (India), Pacific Textiles (Hong Kong) and Manipal Global Education Services (India). Prior to Capital Group, he was a Partner at McKinsey & Co. in Mumbai and served several mid to large sized business groups on a range of initiatives, with a primary focus on business and portfolio strategy.
4.	Terms & conditions of appointment	As mentioned in the resolution at item no. 4
5.	Remuneration sought to be paid	As mentioned in the resolution at item no. 4
6.	Remuneration last drawn	Not Applicable
7.	Date of first appointment on the Board	1 <sup>st</sup> August, 2022
8.	Shareholding in the Company	Nil
9.	Relationship with other Directors, Manager and other Key Managerial Personnel of Company	Nil
10.	Number of Meetings of Board attended during the year and other Directorships, Membership/ Chairmanship of Committees of other Boards	Number of Meetings of Board attended during F.Y. 2022-23 - Nil Membership/ Chairmanship of Committees of other Boards: NIL Directorships in other Companies: 5

**MS. VIJAYA SAMPATH**

<b>S. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Age	69 years
2.	Qualifications	Ms. Vijaya Sampath holds a bachelor's degree in Arts from Madras University and a law degree from Mysore University. She is also a fellow member of the Institute of Company Secretaries of India. She has attended the Advanced Management Program of Harvard Business School, USA and a program on Managing Strategic Alliances conducted by the Wharton School, University of Pennsylvania, USA.
3.	Experience	Ms. Vijaya Sampath brings 38 years of experience in the legal profession and is proficient in corporate law, joint ventures, mergers and acquisitions and commercial contracts. Ms. Sampath has previously worked with the Indian Aluminium Company. She was also associated with Bharti Airtel Limited for eight years as Group General Counsel and Company Secretary. She was a senior partner of Lakshmikumaran & Sridharan, Advocates for five years from August 2012 until August 2017. She is currently the Ombudsperson of the Bharti Airtel group of companies. She was the chairperson of the FICCI corporate laws committee from 2010 until 2019 and currently serves as its advisor.
4.	Terms & conditions of appointment	As mentioned in the resolution at item no. 5
5.	Remuneration sought to be paid	As mentioned in the resolution at item no. 5
6.	Remuneration last drawn	Not Applicable
7.	Date of first appointment on the Board	1 <sup>st</sup> August, 2022
8.	Shareholding in the Company	Nil
9.	Relationship with other Directors, Manager and other Key Managerial Personnel of Company	Nil
10.	Number of Meetings of Board attended during the year and other Directorships, Membership/ Chairmanship of Committees of other Boards	Number of Meetings of Board attended during F.Y. 2022-23 - Nil Membership/ Chairmanship of Committees of other Boards: Chairmanship: 4 Membership: 15  Directorships in other Companies: 10

**MANKIND PHARMA LIMITED**

Registered Office: 208, Okhla Industrial Estate, Phase – III, New Delhi-110020.  
 Ph.: 011-47476600, Fax: 011-46541383, email: [contact@mankindpharma.com](mailto:contact@mankindpharma.com),  
 website: [www.mankindpharma.com](http://www.mankindpharma.com)  
 CIN: U74899DL1991PLC044843

**FORM NO. MGT -11****Proxy Form**

*[Pursuant to the provisions of Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]*

Name of the Member(s):

Registered Address:

E-mail ID

Folio No. / Client ID:

DP ID:

I/We being the Member of Mankind Pharma Limited holding \_\_\_\_\_ equity shares of ₹1/- each of the above named Company, hereby appoint: -

1. Name: \_\_\_\_\_ E-mail Id: \_\_\_\_\_

Address: \_\_\_\_\_

Signature: \_\_\_\_\_ or failing him

2. Name: \_\_\_\_\_ E-mail Id: \_\_\_\_\_

Address: \_\_\_\_\_

Signature: \_\_\_\_\_

as my/our proxy to attend and vote for me/us and on my/our behalf at the 31<sup>st</sup> Annual General Meeting of the Company, to be held at a shorter notice on Tuesday, 9<sup>th</sup> August, 2022 at 208, Okhla Industrial Estate, Phase – III, New Delhi-110020 and at any adjournment(s) thereof, in respect of the resolutions, as indicated below: -


1. To receive, consider and adopt: -
  - a. The Standalone Audited Financial Statements for the financial year ended 31<sup>st</sup> March, 2022 and the Reports of the Board of Directors and Auditors thereon.
  - b. The Consolidated Audited Financial Statements for the financial year ended 31<sup>st</sup> March, 2022 and the Reports of the Auditors thereon.
2. To appoint a director in place of Mr. Ramesh Juneja (DIN: 00283399), who retires by rotation and being eligible, offers himself for re-appointment.
3. Appointment of M/s Bhagi Bhardwaj Gaur & Co., Chartered Accountants as Joint Statutory Auditors of the Company.
4. Appointment of Mr. Vivek Kalra (DIN: 00426240) as an Independent Director of the Company.
5. Appointment of Ms. Vijaya Sampath (DIN: 00641110) as an Independent Director of the Company.
6. Approval for adoption of restated Articles of Association of the Company
7. Approval of Mankind Employee Stock Option Scheme 2022

8. Approval for grant of Employee Stock Options to employees of subsidiary companies under Mankind Employee Stock Option Scheme 2022
9. Approval for grant of Employee Stock Option to employees of group company(ies)/associates under Mankind Employee Stock Option Scheme 2022
10. Increase in investment limits for non-resident Indians and overseas citizens of India.
11. Ratification of the remuneration of the Cost Auditor for the financial year 2022-23.

Signed this ..... day of .....2022.

Signature of Member(s): \_\_\_\_\_

Signature of the Proxy holder(s): \_\_\_\_\_



**Note: This Form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company before the commencement of the meeting.**

**MANKIND PHARMA LIMITED**

Registered Office: 208, Okhla Industrial Estate, Phase – III, New Delhi-110020.  
Ph.: 011-47476600, Fax: 011-46541383, email: [contact@mankindpharma.com](mailto:contact@mankindpharma.com),  
website: [www.mankindpharma.com](http://www.mankindpharma.com)  
CIN: U74899DL1991PLC044843

**ATTENDANCE SLIP****31<sup>st</sup> Annual General Meeting – 9<sup>th</sup> August, 2022****Name of the Member/Proxy in Block Letters:****Folio/DP ID-Client ID:****No. of shares held:**

I certify that I am a registered Shareholder/proxy for the registered Shareholder of the Company and hereby record my presence at the 31<sup>st</sup> Annual General Meeting of the Company on 9<sup>th</sup> August, 2022 at 11:00 AM at 208, Okhla Industrial Estate, Phase – III, New Delhi-110020.

---

Signature of the Member/Proxy

**Note: Please fill this attendance slip and hand it over at the entrance of the hall.**

**Consent by Shareholder for shorter notice  
[Pursuant to Section 101 (1) of the Companies Act, 2013]**

To,

The Board of Directors  
Mankind Pharma Limited  
208, Okhla Industrial Estate,  
Phase-III, New Delhi-110020


I/We \_\_\_\_\_ holding \_\_\_\_\_ equity shares of ₹1/- each in the Company in my own name. Presently, I/We control \_\_\_% of the share capital of Mankind Pharma Limited.

I/We hereby give my/our consent, pursuant to the provisions of Section 101 (1) of the Companies Act, 2013 to hold the Annual General Meeting of the Company at a shorter notice on Tuesday, 9<sup>th</sup> August, 2022 at 11:00 AM (IST) at its registered office at 208, Okhla Industrial Estate, Phase III, New Delhi 110020, India.

Name:

Date:

**ROUTE MAP OF THE VENUE OF 31<sup>ST</sup> ANNUAL GENERAL MEETING OF**  
**MANKIND PHARMA LIMITED**



**Mankind Pharma Limited**

Registered Office:

208, Okhla Industrial Estate,  
Phase – III, New Delhi-110020.

CIN: U74899DL1991PLC044843

Tel. No.: 011-47476600

Fax No.: 011-46541382